EZH2-IN-9
Code | Size | Price |
---|
TAR-T64208-5mg | 5mg | £1,167.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T64208-50mg | 50mg | £2,307.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T64208-100mg | 100mg | £2,898.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
EZH2-IN-9 is a potent inhibitor of EZH2, whose overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) cause abnormal elevations in H3K27me3 and contribute to the growth and development of many tumours (e.g. breast cancer, prostate cancer, leukaemia, etc.). EZH2-IN-9 has shown potential for cancer research (information from patent WO2021180235A1, compound 17).
CAS:
2700897-24-9
Molecular Weight:
596.09
Purity:
0.98
SMILES:
CSc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(Cl)c2OC(C)(Oc2c1C)[C@H]1CC[C@@H](CC1)C(=O)N1CC(F)(F)C1